Tests sleep apnea treatment in adults with atrial fibrillation
Tests a home sleep screening and treatment program in adults with atrial fibrillation.
Plain-language title generated from the registry record
Registry title: Structured Testing and Treatment for Obstructive Sleep Apnea in Patients With Atrial Fibrillation
Key facts
- Where
- Edegem and Hasselt, BelgiumSee the 2 sites
Where in Belgium
- University Hospital of AntwerpEdegem, BelgiumTaking people
- Jessa HospitalHasselt, BelgiumTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital, Antwerp
- Trial code
- NCT06263608
- Record updated
- 8 May 2026
- Original description
The main goal of this prospective pre-post implementation study is to investigate how a structured testing and treatment program for obstructive sleep apnea using the NOX T3s device and a Fitbit smartwatch with the FibriCheck algorithm impacts the proportion of atrial fibrillation (AF) in an AF population.Read full original descriptionShow less
STAROSA Trial - Structured Testing and Treatment for Obstructive Sleep Apnea in Patients With Atrial Fibrillation
The main goal of this prospective pre-post implementation study is to investigate how a structured testing and treatment program for obstructive sleep apnea using the NOX T3s device and a Fitbit smartwatch with the FibriCheck algorithm impacts the proportion of atrial fibrillation (AF) in an AF population.
Participants will wear the NOX T3s respiratory polygraphy device for one night at home. In case of a positive obstructive sleep apnea diagnosis, patients will be referred to the sleep clinic for a polysomnography examination. Patients positively diagnosed with polygraph will be monitored semi-continuously with the Fitbit smartwatch for three months. After the polysomnography examination, the positively diagnosed patients will be monitored semi-continuously for another three months after initiation of treatment (mostly continuous positive airway pressure (CPAP) treatment). Additionally, patients will be administered satisfaction, symptom burden and alcohol consumption questionnaires twice: right after the polysomnography examination and after the 3-month treatment.
Inclusion: Patients in whom AF (paroxysmal or persistent) is diagnosed with a 12-lead ECG; Patients who experience symptoms of their AF (mEHRA ≥ 2a); Older than 18 years; Owning a smartphone compatible with Fitbit and FibriCheck applications (i.e. recent versions of Apple iOS or Android drivers); Ability to sign the informed consent.
Exclusion: Prior/recent polysomnography evaluation; Prior/active CPAP/BiPAP/ASV treatment; Cognitive impairment; Pacemaker-dependent heart rhythm; Patients diagnosed with permanent AF or only atrial flutter; Inability to speak or fully understand Dutch.